Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699797 · ClinicalTrials.gov registry record · NA
Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant
A NA study of Sensorineural Hearing Loss and Sensorineural Hearing Loss, Bilateral, sponsored by Envoy Medical Corporation.
- Active
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 7
- Study locations
NCT06699797: Active NA study of Sensorineural Hearing Loss and Sensorineural Hearing Loss, Bilateral, sponsored by Envoy Medical Corporation.
NCT06699797 is a NA study of Sensorineural Hearing Loss and Sensorineural Hearing Loss, Bilateral that is active but no longer recruiting, run by Envoy Medical Corporation. The registered enrollment target is 56 participants, below the 127-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (56% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06699797, a NA study of Sensorineural Hearing Loss and Sensorineural Hearing Loss, Bilateral, is active but no longer recruiting, sponsored by Envoy Medical Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this clinical trial is to learn if the Acclaim CI works to treat severe to profound sensorineural hearing loss in adults. It was also learn about the safety of the Acclaim CI implant. The main questions it aims to answer are: * Does the Acclaim CI device help participants hear words better compared to before the implants? * What medical problems do participants have after the Acclaim CI device was implanted? Participants will: * Have the Acclaim CI implanted; and * Visit the clinical site for checkups and tests at 1-Month, 3-Months, 6-Months, and at 1-year and 2-years after the device has been turned on.
Conditions Studied
Interventions
- DEVICE Acclaim Cochlear Implant
Study Locations (7)
Arizona
- Center for Neurosciences Ear and Hearing Center - Tucson
California
- Shohet Ear Associates - Seal Beach
Florida
- University of Florida Health - Gainesville
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic - Cleveland
Oklahoma
- Hearts for Hearing - Oklahoma City
South Carolina
- MUSC Health - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2028-04 |
| Phase | NA |
What the registry record for NCT06699797 still lists
NCT06699797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 127-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (56% lower).
The record links to 6 conditions, with Sensorineural Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which Acclaim Cochlear Implant is the first listed.
NCT06699797 lists 7 locations in 7 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06699797 about?
NCT06699797 is a clinical study titled "Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant". The goal of this clinical trial is to learn if the Acclaim CI works to treat severe to profound sensorineural hearing loss in adults. It was also learn about the safety of the Acclaim CI implant. The main questions it aims to answer are: * Does the Acclaim CI device help participants hear words bet...
What is the current status of trial NCT06699797?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2025-02-06. Estimated completion is 2028-04.
What conditions does trial NCT06699797 study?
This clinical trial studies the following conditions: Sensorineural Hearing Loss, Sensorineural Hearing Loss, Bilateral, Sensori-Neural Deafness, Sensorineural Hearing Loss (Disorder), Sensorineural Hearing Loss, Profound.
What interventions are being tested in trial NCT06699797?
The interventions under investigation include: Acclaim Cochlear Implant (DEVICE).
Who is sponsoring clinical trial NCT06699797?
This trial is sponsored by Envoy Medical Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699797 being conducted?
This trial has 7 study locations across Arizona, California, Florida, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sensorineural Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06699797's enrollment target sits among peer trials
56 6th of 13 higher than 8 of 13 other Sensorineural Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sensorineural Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Perceptual Adaptation Following Cochlear Implantation (Aim 3a)
RECRUITING · NA
-
Effects of Clear Speech on Listening Effort and Memory in Sentence Processing
RECRUITING · NA
-
Social Influences on Sensorimotor Integration of Speech Production and Perception During Early Vocal Learning
RECRUITING · NA
-
The Effect of Sound Stimulation on Pure-tone Hearing Threshold
COMPLETED · NA
-
Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System
COMPLETED · NA
-
Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI